Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Providence Health & Services
- 14 Feb 2019 Planned number of patients changed from 18 to 28.
- 25 Jun 2018 Planned number of patients changed from 6 to 18.
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.